Cargando…

Metastatic Uveal Melanoma: Treatment Strategies and Survival—Results from the Dutch Melanoma Treatment Registry

Uveal melanoma (UM) is the most common primary intraocular tumor in adults. Up to 50% of UM patients will develop metastases. We present data of 175 metastatic UM patients diagnosed in the Netherlands between July 2012 and March 2018. In our cohort, elevated lactate dehydrogenase level (LDH) is an i...

Descripción completa

Detalles Bibliográficos
Autores principales: Jochems, Anouk, van der Kooij, Monique K., Fiocco, Marta, Schouwenburg, Maartje G., Aarts, Maureen J., van Akkooi, Alexander C., van den Berkmortel, Franchette W.P.J., Blank, Christian U., van den Eertwegh, Alfonsus J.M., Franken, Margreet G., de Groot, JanWillem B., Haanen, John B.A.G., Hospers, Geke A.P., Koornstra, Rutger H., Kruit, Wim H.J., Louwman, Marieke, Piersma, Djura, van Rijn, Rozemarijn S., Suijkerbuijk, Karijn P.M., ten Tije, Albert J., Vreugdenhil, Gerard, Wouters, Michel W.J.M., van Zeijl, Michiel C.T., van der Hoeven, Koos J.M., Kapiteijn, Ellen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678641/
https://www.ncbi.nlm.nih.gov/pubmed/31323802
http://dx.doi.org/10.3390/cancers11071007
_version_ 1783441149200957440
author Jochems, Anouk
van der Kooij, Monique K.
Fiocco, Marta
Schouwenburg, Maartje G.
Aarts, Maureen J.
van Akkooi, Alexander C.
van den Berkmortel, Franchette W.P.J.
Blank, Christian U.
van den Eertwegh, Alfonsus J.M.
Franken, Margreet G.
de Groot, JanWillem B.
Haanen, John B.A.G.
Hospers, Geke A.P.
Koornstra, Rutger H.
Kruit, Wim H.J.
Louwman, Marieke
Piersma, Djura
van Rijn, Rozemarijn S.
Suijkerbuijk, Karijn P.M.
ten Tije, Albert J.
Vreugdenhil, Gerard
Wouters, Michel W.J.M.
van Zeijl, Michiel C.T.
van der Hoeven, Koos J.M.
Kapiteijn, Ellen
author_facet Jochems, Anouk
van der Kooij, Monique K.
Fiocco, Marta
Schouwenburg, Maartje G.
Aarts, Maureen J.
van Akkooi, Alexander C.
van den Berkmortel, Franchette W.P.J.
Blank, Christian U.
van den Eertwegh, Alfonsus J.M.
Franken, Margreet G.
de Groot, JanWillem B.
Haanen, John B.A.G.
Hospers, Geke A.P.
Koornstra, Rutger H.
Kruit, Wim H.J.
Louwman, Marieke
Piersma, Djura
van Rijn, Rozemarijn S.
Suijkerbuijk, Karijn P.M.
ten Tije, Albert J.
Vreugdenhil, Gerard
Wouters, Michel W.J.M.
van Zeijl, Michiel C.T.
van der Hoeven, Koos J.M.
Kapiteijn, Ellen
author_sort Jochems, Anouk
collection PubMed
description Uveal melanoma (UM) is the most common primary intraocular tumor in adults. Up to 50% of UM patients will develop metastases. We present data of 175 metastatic UM patients diagnosed in the Netherlands between July 2012 and March 2018. In our cohort, elevated lactate dehydrogenase level (LDH) is an important factor associated with poorer survival (Hazard Ratio (HR) 9.0, 95% Confidence Interval (CI) 5.63–14.35), and the presence of liver metastases is negatively associated with survival (HR 2.09, 95%CI 1.07–4.08). We used data from the nation-wide Dutch Melanoma Treatment Registry (DMTR) providing a complete overview of the location of metastases at time of stage IV disease. In 154 (88%) patients, the liver was affected, and only 3 patients were reported to have brain metastases. In 63 (36%) patients, mutation analysis was performed, showing a GNA11 mutation in 28.6% and a GNAQ mutation in 49.2% of the analyzed patients. In the absence of standard care of treatment options, metastatic UM patients are often directed to clinical trials. Patients participating in clinical trials are often subject to selection and usually do not represent the entire metastatic UM population. By using our nation-wide cohort, we are able to describe real-life treatment choices made in metastatic UM patients and 1-year survival rates in selected groups of patients.
format Online
Article
Text
id pubmed-6678641
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-66786412019-08-19 Metastatic Uveal Melanoma: Treatment Strategies and Survival—Results from the Dutch Melanoma Treatment Registry Jochems, Anouk van der Kooij, Monique K. Fiocco, Marta Schouwenburg, Maartje G. Aarts, Maureen J. van Akkooi, Alexander C. van den Berkmortel, Franchette W.P.J. Blank, Christian U. van den Eertwegh, Alfonsus J.M. Franken, Margreet G. de Groot, JanWillem B. Haanen, John B.A.G. Hospers, Geke A.P. Koornstra, Rutger H. Kruit, Wim H.J. Louwman, Marieke Piersma, Djura van Rijn, Rozemarijn S. Suijkerbuijk, Karijn P.M. ten Tije, Albert J. Vreugdenhil, Gerard Wouters, Michel W.J.M. van Zeijl, Michiel C.T. van der Hoeven, Koos J.M. Kapiteijn, Ellen Cancers (Basel) Article Uveal melanoma (UM) is the most common primary intraocular tumor in adults. Up to 50% of UM patients will develop metastases. We present data of 175 metastatic UM patients diagnosed in the Netherlands between July 2012 and March 2018. In our cohort, elevated lactate dehydrogenase level (LDH) is an important factor associated with poorer survival (Hazard Ratio (HR) 9.0, 95% Confidence Interval (CI) 5.63–14.35), and the presence of liver metastases is negatively associated with survival (HR 2.09, 95%CI 1.07–4.08). We used data from the nation-wide Dutch Melanoma Treatment Registry (DMTR) providing a complete overview of the location of metastases at time of stage IV disease. In 154 (88%) patients, the liver was affected, and only 3 patients were reported to have brain metastases. In 63 (36%) patients, mutation analysis was performed, showing a GNA11 mutation in 28.6% and a GNAQ mutation in 49.2% of the analyzed patients. In the absence of standard care of treatment options, metastatic UM patients are often directed to clinical trials. Patients participating in clinical trials are often subject to selection and usually do not represent the entire metastatic UM population. By using our nation-wide cohort, we are able to describe real-life treatment choices made in metastatic UM patients and 1-year survival rates in selected groups of patients. MDPI 2019-07-18 /pmc/articles/PMC6678641/ /pubmed/31323802 http://dx.doi.org/10.3390/cancers11071007 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Jochems, Anouk
van der Kooij, Monique K.
Fiocco, Marta
Schouwenburg, Maartje G.
Aarts, Maureen J.
van Akkooi, Alexander C.
van den Berkmortel, Franchette W.P.J.
Blank, Christian U.
van den Eertwegh, Alfonsus J.M.
Franken, Margreet G.
de Groot, JanWillem B.
Haanen, John B.A.G.
Hospers, Geke A.P.
Koornstra, Rutger H.
Kruit, Wim H.J.
Louwman, Marieke
Piersma, Djura
van Rijn, Rozemarijn S.
Suijkerbuijk, Karijn P.M.
ten Tije, Albert J.
Vreugdenhil, Gerard
Wouters, Michel W.J.M.
van Zeijl, Michiel C.T.
van der Hoeven, Koos J.M.
Kapiteijn, Ellen
Metastatic Uveal Melanoma: Treatment Strategies and Survival—Results from the Dutch Melanoma Treatment Registry
title Metastatic Uveal Melanoma: Treatment Strategies and Survival—Results from the Dutch Melanoma Treatment Registry
title_full Metastatic Uveal Melanoma: Treatment Strategies and Survival—Results from the Dutch Melanoma Treatment Registry
title_fullStr Metastatic Uveal Melanoma: Treatment Strategies and Survival—Results from the Dutch Melanoma Treatment Registry
title_full_unstemmed Metastatic Uveal Melanoma: Treatment Strategies and Survival—Results from the Dutch Melanoma Treatment Registry
title_short Metastatic Uveal Melanoma: Treatment Strategies and Survival—Results from the Dutch Melanoma Treatment Registry
title_sort metastatic uveal melanoma: treatment strategies and survival—results from the dutch melanoma treatment registry
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678641/
https://www.ncbi.nlm.nih.gov/pubmed/31323802
http://dx.doi.org/10.3390/cancers11071007
work_keys_str_mv AT jochemsanouk metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry
AT vanderkooijmoniquek metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry
AT fioccomarta metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry
AT schouwenburgmaartjeg metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry
AT aartsmaureenj metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry
AT vanakkooialexanderc metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry
AT vandenberkmortelfranchettewpj metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry
AT blankchristianu metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry
AT vandeneertweghalfonsusjm metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry
AT frankenmargreetg metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry
AT degrootjanwillemb metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry
AT haanenjohnbag metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry
AT hospersgekeap metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry
AT koornstrarutgerh metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry
AT kruitwimhj metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry
AT louwmanmarieke metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry
AT piersmadjura metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry
AT vanrijnrozemarijns metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry
AT suijkerbuijkkarijnpm metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry
AT tentijealbertj metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry
AT vreugdenhilgerard metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry
AT woutersmichelwjm metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry
AT vanzeijlmichielct metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry
AT vanderhoevenkoosjm metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry
AT kapiteijnellen metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry